Why the study?
Does atorvastatin reduce AF recurrence in patients with atrial fibrillation/flutter undergoing DC cardioversion?
Population
64 patients with atrial fibrillation/flutter (AF) undergoing DC cardioversion (CV)
Comparison
Atorvastatin 80 mg before CV, continued for 12… vs Matching placebo before CV, continued for 12…
Design
RCT, randomized, double-blinded, placebo-controlled
Follow-up
Up to 12 months or until AF recurred
Authors
Loading...
Atorvastatin should not be used to prevent post-cardioversion AF recurrence; challenges inflammation-targeted strategies for rhythm control.
Does atorvastatin reduce AF recurrence in patients with atrial fibrillation/flutter undergoing DC cardioversion?
High-dose atorvastatin did not reduce the recurrence of atrial fibrillation after DC cardioversion, despite significantly lowering selective markers of inflammation.
Negi et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: